Comparison of the QUANTIPLEX HIV-1 RNA 2.0 Assay with the AMPLICOR HIV- 1 MONITOR 1.0 Assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy

Journal of Clinical Microbiology

Volumn 36, Issue 11, 1998, Pages 3392-3395

  Segondy, Michel ^a,e   Izopet, Jacques ^b   Pellegrin, Isabelle ^c   Montes, Brigitte ^a   Dumon, Beatrice ^c   Pasquier, Christophe ^b   Peeters, Martine ^d   Fleury, Herve J A ^c   Puel, Jacqueline ^b   Reynes, Jacques ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^e HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; STAVUDINE; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; STANDARDIZATION; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0031671624     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.36.11.3392-3395.1998     Document Type: Article

References (19)

1. Brambilla, D., S. Leung, J. Lew, J. Todd, S. Herman, M. Cronin, D. E. Shapiro, J. Bremer, C. Hanson, G. V. Hillyer, G. D. McSherry, R. S. Sperling, R. W. Coombs, and P. S. Reichelderfer. 1998. Absolute copy number and relative change in determination of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons. J. Clin. Microbiol. 36:311-314.
2. Christopherson, C., J. Sninsky, and S. Kwok. 1997. The effects of internal primer-template mismatches on RT-PCR: HIV-1 model studies. Nucleic Acids Res. 25:654-658.
3. Clementi, M., S. Menzo, P. Bagnarelli, A. Valenza, S. Paolucci, R. Sampaolesi, A. Manzin, and P. E. Varaldo. 1996. Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection. Clin. Microbiol. Rev. 9:135-147.
4. Coombs, R. W., S. L. Welles, C. Hooper, P. S. Reichelderfer, R. T. D'Aquila, A. J. Japour, V. A. Johnson, D. R. Kuritzkes, D. D. Richman, S. Kwok, J. Todd, J. B. Jackson, V. DeGruttola, C. S. Crumpacker, and J. Kahn for the AIDS Clinical Trials Group (ACTG) 116B/117 Study Team and the ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. 1996. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J. Infect. Dis. 174:704-712.
5. Coste, J., B. Montès, J. Reynes, M. Peeters, C. Segarra, J. P. Vendrell, E. Delaporte, and M. Segondy. 1996. Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J. Med. Virol. 50:293-302.
6. Jackson, J. B., S. Y. Kwok, J. J. Sninsky, J. S. Hopsicker, K. J. Sannerud, F. S. Rhame, K. Henry, M. Simpson, and H. H. Balfour, Jr. 1990. Human immunodeficiency virus type 1 detected in all seropositive symptomatic and asymptomatic individuals. J. Clin. Microbiol. 28:16-19.
7. Katzenstein, D. A., S. M. Hammer, M. D. Hughes, H. Gundacker, J. B. Jackson, S. Fiscus, S. Rasheed, T. Elbeik, R. Reichman, A. Japour, T. C. Merigan, and M. S. Hirsch for the AIDS Clinical Trials Group Study 175 Virology Study Team. 1996. The relation of virologie and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic milliliter. N. Engl. J. Med. 335:1091-1098.
8. Kern, D., M. Collins, T. Fultz, J. Detmer, S. Hamren, J. J. Peterkin, P. Sheridan, M. Urdea, R. White, T. Yeghiazarian, and J. Todd. 1996. An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 34:3196-3202.
9. Marschner, I. C., A. C. Collier, R. W. Coombs, R. T. D'Aquila, V. DeGruttola, M. A. Fischl, S. M. Hammer, M. D. Hughes, V. A Johnson, D. A. Katzenstein, D. D. Richman, L. M. Smeaton, S. A. Spector, and M. S. Saag. 1998. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J. Infect. Dis. 177:40-47.
10. Mellors, J. W., C. R. Rinaldo, P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
11. Mulder, J., N. McKinney, C. Christopherson, J. Sninsky, L. Greenfield, and S. Kwok. 1994. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32:292-300.
12. Mulder, J., R. Resnick, B. Saget, S. Scheibel, S. Herman, H. Payne, R. Harrigan, and S. Kwok. 1997. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J. Clin. Microbiol. 35:1278-1280.
13. Nolte, F. S., J. Boysza, C. Thurmond, W. S. Clark, and J. L. Lennox. 1998. Clinical comparison of an enhanced-sensitivity branched-DNA assay and reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 36:716-720.
14. Quillent, C., E. Nerrienet, P. Metais, J. Braun, M. G. Enouf, G. Gonzales-Canali, H. Chenal, and A. Beretta. 1997. Improved detection of subtype A of HIV RNA in plasma using a modified RT-PCR kit (HIV Monitor, Roche) containing an expanded set of primers, abstr. 301, p. 36. In Program and abstracts of the Sixth Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, Germany.
15. Revets, H., D. Marissens, S. De Wit, P. Lacor, N. Clumeck, S. Lauwers, and G. Zissis. 1996. Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV Monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 34:1058-1064.
16. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada.
17. Schuurman, R., D. Descamps, G. J. Weverling, S. Kaye, J. Tijnagel, I. Williams, R. van Leeuwen, R. Tedder, C. A. B. Boucher, F. Brun-Vézinet, and C. Loveday. 1996. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 34:3016-3022.
18. Triques, K., J. Coste, J. L. Perret, E. Mpoudi, J. Reynes, M. Segondy, E. Delaporte, S. Herman, K. Dreyer, J. Wang, J. Gomes, J. Spadoro, and M. Peeters. 1998. Performance of three versions of the AMPLICOR HIV-1 MONITOR test on clinical samples of HIV-1 subtypes A, B, C, D, E and G, abstr. 305, p. 137. In Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, Ill.
19. van Gemen, B., T. Kievits, R. Schukkink, D. van Strijp, L. T. Malek, R. Sooknanan, H. G. Huisman, and P. Lens. 1993. Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection. J. Virol. Methods 43:177-187.